Literature DB >> 33024004

Machine Learning Approaches Reveal Metabolic Signatures of Incident Chronic Kidney Disease in Individuals With Prediabetes and Type 2 Diabetes.

Jialing Huang1,2,3, Cornelia Huth2,3, Marcela Covic1,2,3, Martina Troll1,2, Jonathan Adam1,2, Sven Zukunft4, Cornelia Prehn4, Li Wang1,2,5, Jana Nano2,3, Markus F Scheerer6, Susanne Neschen6, Gabi Kastenmüller7, Karsten Suhre8, Michael Laxy9, Freimut Schliess10, Christian Gieger1,2,3, Jerzy Adamski4,11,12, Martin Hrabe de Angelis3,6,12, Annette Peters2,3, Rui Wang-Sattler13,2,3.   

Abstract

Early and precise identification of individuals with prediabetes and type 2 diabetes (T2D) at risk for progressing to chronic kidney disease (CKD) is essential to prevent complications of diabetes. Here, we identify and evaluate prospective metabolite biomarkers and the best set of predictors of CKD in the longitudinal, population-based Cooperative Health Research in the Region of Augsburg (KORA) cohort by targeted metabolomics and machine learning approaches. Out of 125 targeted metabolites, sphingomyelin C18:1 and phosphatidylcholine diacyl C38:0 were identified as candidate metabolite biomarkers of incident CKD specifically in hyperglycemic individuals followed during 6.5 years. Sets of predictors for incident CKD developed from 125 metabolites and 14 clinical variables showed highly stable performances in all three machine learning approaches and outperformed the currently established clinical algorithm for CKD. The two metabolites in combination with five clinical variables were identified as the best set of predictors, and their predictive performance yielded a mean area value under the receiver operating characteristic curve of 0.857. The inclusion of metabolite variables in the clinical prediction of future CKD may thus improve the risk prediction in people with prediabetes and T2D. The metabolite link with hyperglycemia-related early kidney dysfunction warrants further investigation.
© 2020 by the American Diabetes Association.

Entities:  

Year:  2020        PMID: 33024004     DOI: 10.2337/db20-0586

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  5 in total

Review 1.  Machine learning for risk stratification in kidney disease.

Authors:  Faris F Gulamali; Ashwin S Sawant; Girish N Nadkarni
Journal:  Curr Opin Nephrol Hypertens       Date:  2022-08-10       Impact factor: 3.416

2.  TIGER: technical variation elimination for metabolomics data using ensemble learning architecture.

Authors:  Siyu Han; Jialing Huang; Francesco Foppiano; Cornelia Prehn; Jerzy Adamski; Karsten Suhre; Ying Li; Giuseppe Matullo; Freimut Schliess; Christian Gieger; Annette Peters; Rui Wang-Sattler
Journal:  Brief Bioinform       Date:  2022-03-10       Impact factor: 11.622

3.  Validation of Candidate Phospholipid Biomarkers of Chronic Kidney Disease in Hyperglycemic Individuals and Their Organ-Specific Exploration in Leptin Receptor-Deficient db/db Mouse.

Authors:  Jialing Huang; Marcela Covic; Cornelia Huth; Martina Rommel; Jonathan Adam; Sven Zukunft; Cornelia Prehn; Li Wang; Jana Nano; Markus F Scheerer; Susanne Neschen; Gabi Kastenmüller; Christian Gieger; Michael Laxy; Freimut Schliess; Jerzy Adamski; Karsten Suhre; Martin Hrabe de Angelis; Annette Peters; Rui Wang-Sattler
Journal:  Metabolites       Date:  2021-02-03

Review 4.  Metabolomics in Diabetes and Diabetic Complications: Insights from Epidemiological Studies.

Authors:  Qiao Jin; Ronald Ching Wan Ma
Journal:  Cells       Date:  2021-10-21       Impact factor: 6.600

5.  Estimated Renal Metabolomics at Reperfusion Predicts One-Year Kidney Graft Function.

Authors:  Thomas Verissimo; Anna Faivre; Sebastian Sgardello; Maarten Naesens; Sophie de Seigneux; Gilles Criton; David Legouis
Journal:  Metabolites       Date:  2022-01-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.